Transdermal ethinyl estradiol and norelgestromin for contraception

References

• Zurawin RK, Ayensu-Coker L. Innovations in contraception: a review. Clin. Obstet. Gynecol.50(2), 425–439 (2007).
   PubMedGoogle Scholar
• Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect. Sex. Reprod. Health38(2), 90–96 (2006).
   PubMed Web of Science ®Google Scholar
• Trussell J. The cost of unintended pregnancy in the United States. Contraception75(3), 168–170 (2007).
   PubMed Web of Science ®Google Scholar
• Amaral G, Foster DG, Biggs MA, Jasik CB, Judd S, Brindis CD. Public savings from the prevention of unintended pregnancy: a cost analysis of family planning services in California. Health Serv. Res.42(5), 1960–1980 (2007).
   PubMedGoogle Scholar
• Potts RO, Lobo RA. Transdermal drug delivery: clinical considerations for the obstetrician-gynecologist. Obstet. Gynecol.105(5 Pt 1), 953–961 (2005).
   PubMed Web of Science ®Google Scholar
• Brown L, Langer R. Transdermal delivery of drugs. Annu. Rev. Med.39, 221–229 (1988).
   PubMed Web of Science ®Google Scholar
• Abrams LS, Skee D, Natarajan J, Wong FA. Pharmacokinetic overview of Ortho Evra/Evra. Fertil. Steril.77(2 Suppl. 2), S3–S12 (2002).
   PubMed Web of Science ®Google Scholar
• Samisoe G. Transdermal hormone therapy: gels and patches. Climacteric7, 347–356 (2004).
   PubMed Web of Science ®Google Scholar
• Munoz A. OESCLIM: an advanced delivery system for HRT. Maturitas33(Suppl. 1), S39–S47 (1999).
   PubMed Web of Science ®Google Scholar
• Ortho Evra™ (norelgestromin/ethinyl estradiol transdermal system) [product labeling]. Ortho-McNeil Pharmaceutical Inc., Raritan, NJ, USA (2006).
   Google Scholar
• Abrams LS, Skee D, Natarajan J, Wong F, Anderson GD. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyl estradiol at four application sites. Br. J. Clin. Pharmacol.53(2), 141–146 (2002).
   PubMed Web of Science ®Google Scholar
• Pierson RA, Archer DF, Moreau M, Shangold GA, Fisher AC, Creasy GW. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil. Steril.80(1), 34–42 (2003).
   PubMed Web of Science ®Google Scholar
• White T, Jain JK, Stanczyk FZ. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. Am. J. Obstet. Gynecol.192(6), 2055–2059 (2005).
   PubMed Web of Science ®Google Scholar
• Hedon B, Helmerhorst FM, Cronje HS, Shangold, G, Fisher AC, Creasy G. Comparison of efficacy, cycle control, compliance, and safety in users of a contraceptive patch vs an oral contraceptive. Int. J. Gynaecol. Obstet.70(1 Suppl.), 78 (2000).
   Google Scholar
• Audet MC, Moreau M, Koltun WD et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA285(18), 2347–2354 (2001).
   PubMed Web of Science ®Google Scholar
• Smallwood GH, Meador ML, Lenihan JP et al. Efficacy and safety of a transdermal contraceptive system. Obstet. Gynecol.98, 799–805 (2001).
   PubMed Web of Science ®Google Scholar
• Urdl W, Apter D, Alperstein A et al. Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception. Eur. J. Obstet. Gynecol. Reprod. Biol.121(2), 202–210 (2005).
   PubMed Web of Science ®Google Scholar
• Zacur HA, Hedon B, Mansour D, Shangold G, Fisher AC, Creasy GW. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil. Steril.77(2 Suppl. 2), S32–S35 (2002).
   Web of Science ®Google Scholar
• Jick SS, Kaye JA, Russman S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception73(3), 223–228 (2006).
   PubMed Web of Science ®Google Scholar
• Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet. Gynecol.109(2 Pt 1), 339–346 (2007).
   PubMed Web of Science ®Google Scholar
• Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet. Gynecol.110(3), 587–593 (2007).
   PubMed Web of Science ®Google Scholar
• Jick SS, Kaye JA, Russman S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception73(6), 566–570 (2006).
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists (ACOG). Thromboembolism in pregnancy. In: ACOG Practice Bulletin 19. ACOG, Washington DC, USA (2000).
   Google Scholar
• Jick SS, Jick H. The contraceptive patch in relation to ischemic stroke and acute myocardial infarction. Pharmacotherapy27(2), 218–220 (2007).
   PubMed Web of Science ®Google Scholar
• Abrams LS, Skee DM, Natarajan J, Wong FA, Lasseter KC. Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants. Contraception64(5), 287–294 (2001).
   PubMed Web of Science ®Google Scholar
• Weisberg F, Bouchard C, Moreau M et al. Preference for and satisfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: an open-label, multicentre study. J. Obstet. Gynaecol. Can.27(4), 350–359 (2005).
   PubMedGoogle Scholar
• Stewart FH, Kaunitz AM, LaGuardia KD, Karvois DL, Fisher AC, Friedman AJ. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet. Gynecol.105(6), 1389–1396 (2005).
   PubMed Web of Science ®Google Scholar
• Intercontinental Marketing Services (IMS) Health, Norwalk, CT, USA (2009).
   Google Scholar